ArticleJournal of clinical laboratory analysis2021
Immune-related eight-lncRNA signature for improving prognosis prediction of lung adenocarcinoma.
Article in Journal of clinical laboratory analysis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Interpretable graph Kolmogorov-Arnold networks for multi-cancer classification and biomarker identification using multi-omics data.Scientific reports · 2025Article
- Vitamin D Reshapes Genomic Hierarchies in Skin Cells: lncRNA-Driven Responses in Carcinoma Versus Transcription Factor-Based Regulation in Healthy Skin.International journal of molecular sciences · 2025Article
- Regulation of overexpression lncRNA ATP2B1-AS1 on lung adenocarcinoma progression.Journal of cardiothoracic surgery · 2024Article
- Novel pyroptosis-related lncRNAs and ceRNAs predict osteosarcoma prognosis and indicate immune microenvironment signatures.Heliyon · 2023Article
- Machine learning-based immune prognostic model and ceRNA network construction for lung adenocarcinoma.Journal of cancer research and clinical oncology · 2023Article
- LncRNA SATB2-AS1 promotes tumor growth and metastasis and affects the tumor immune microenvironment in osteosarcoma by regulating SATB2.Journal of bone oncology · 2023Article
- Risk coefficient model of necroptosis-related lncRNA in predicting the prognosis of patients with lung adenocarcinoma.Scientific reports · 2022Article
- Development of six immune-related lncRNA signature prognostic model for smoking-positive lung adenocarcinoma.Journal of clinical laboratory analysis · 2022Article
- TNF-α Induced Myotube Atrophy in C2C12 Cell Line Uncovers Putative Inflammatory-Related lncRNAs Mediating Muscle Wasting.International journal of molecular sciences · 2022Article
- Prognostic prediction of clear cell renal cell carcinoma based on lipid metabolism-related lncRNA risk coefficient model.Frontiers in genetics · 2022Article
- Immune-related eight-lncRNA signature for improving prognosis prediction of lung adenocarcinoma.Journal of clinical laboratory analysis · 2021Article
- Identification of Novel Tumor Microenvironment-Related Long Noncoding RNAs to Determine the Prognosis and Response to Immunotherapy of Hepatocellular Carcinoma Patients.Frontiers in molecular biosciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung adenocarcinoma (LUAD) is the leading cause of cancer-related deaths worldwide. Therefore, the identification of a novel prediction signature for predicting the prognosis risk and survival outcomes is urgently demanded.
methodsWe integrated a machine-learning frame by combing the Cox regression and Least Absolute Shrinkage and Selection Operator (LASSO) regression model to identify the LUAD-related long non-coding RNA (lncRNA) survival biomarkers. Subsequently, the Spearman correlation test was employed to interrogate the relationships between lncRNA signature and tumor immunity and constructed the competing endogenous RNA (ceRNA) network.
resultsHerein, we identified an eight-lncRNA signature (PR-lncRNA signature, NPSR1-AS1, SATB2-AS1, LINC01090, FGF12-AS2, AC005256.1, MAFA-AS1, BFSP2-AS1, and CPC5-AS1), which contributes to predicting LUAD patient's prognosis risk and survival outcomes. The PR-lncRNA signature has also been confirmed as the robust signature in independent datasets. Further parsing of the LUAD tumor immune infiltration showed the PR-lncRNAs were closely associated with the abundance of multiple immune cells infiltration and the expression of MHC molecules. Furthermore, by constructing the PR-lncRNA-related ceRNA network, we interrogated more potential anti-cancer therapy targets.
conclusionlncRNAs, as emerging cancer biomarkers, play an important role in a variety of cancer processes. Identification of PR-lncRNA signatures allows us to better predict patient's survival outcomes and disease risk. Finally, the PR-lncRNA signatures could help us to develop novel LUAD anti-cancer therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.